A research group at Osaka University Graduate School compiled the cumulative vaccination rate (nationwide value) for each year of birth for the HPV vaccine (a preventive vaccine for cervical cancer, etc.) up until fiscal year 2022. For the first time, it became clear that the vaccination rate has not recovered even after active recommendation was resumed.
Public funding for the HPV vaccine began in 2010, and it became a routine vaccination in 2013, but the vaccination rate dropped sharply due to reports of side effects and the Ministry of Health, Labor and Welfare refraining from active recommendations, and it was effectively stopped. Individual notification was provided to eligible individuals from 2020, and active recommendations were resumed from 2022, but the recovery of the vaccination rate remains a challenge. The research group corrected the number of vaccinated people from the previous age at vaccination to the year of birth (by school year), and calculated the cumulative routine vaccination rate up to 2022.
その結果、公費助成で接種が進んだ接種世代（1994~1999年度生まれ）で平均71・96%、積極的勧奨差し控えで接種率が激減した停止世代（2000~2003年度生まれ）で平均4.62%、個別案内を受けた世代（2004~2009年度生まれ）で平均16.16%、積極的勧奨が再開された世代（2010年度生まれ）で2.83%と、生まれ年度で差が大きく、積極的勧奨再開後も接種率は未回復と判明した。
さらに、2023年度以降も2022年度の接種状況が維持された場合、定期接種終了（高1終了）時までの累積接種率は、個別案内を受けた世代（2004~2009年度生まれ）で平均28.83%とやや上昇するも、積極的勧奨再開に接した世代（2010年度以降生まれ）は43・16%で頭打ちとなる。これはWHOが世界の子宮頸がん排除（罹患率：4人以下／10万人）のために設定した目標値90%の半分未満だ。
In order to reduce cervical cancer cases in the future, efforts to increase HPV vaccination rates and strengthen encouragement to undergo cervical cancer screening will be necessary, and the results of this study are said to be important information for considering future cervical cancer countermeasures.
Paper information:[JAMA Network Open] Human papillomavirus vaccination by birth fiscal year in Japan
